Oct 15, 2020
Tarsus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering
IRVINE, Calif. , Oct. 15, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. , (“Tarsus”) a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions, today
Jul 16, 2020
Tarsus Pharmaceuticals Announces Appointment of New COO and CFO
Sesha Neervannan, PhD, to assume position of Chief Operating Officer; Leo Greenstein to assume position of Chief Financial Officer IRVINE, Calif., July 16, 2020 /PRNewswire/ -- Tarsus Pharmaceuticals, a clinical-stage biopharmaceutical company, today announced the appointment of two pharmaceutical
Jan 08, 2020
Tarsus Pharmaceuticals Raises $60 Million in Series B Financing
Capital to enable Phase 2b/3 trial for lead product TP-03 in Demodex blepharitis and additional clinical pipeline development IRVINE, Calif., Jan. 8, 2020 /PRNewswire/ -- Tarsus Pharmaceuticals, a clinical-stage biopharmaceutical company, today announced the completion of $60 million in Series B